Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001

Blood (2024) 144 (Supplement 1): 3649.

https://doi.org/10.1182/blood-2024-199274

Published: 2024

Journal Articles

Pediatric RISE: Development of a Poverty-Targeted Cash Support Intervention for Pediatric Cancer

Colleen A. Kelly, Morgan A. Paul, Jennifer Kellett, Sunyu Kang, Anna Revette, Rahela Aziz-Bose, Leanne Duhaney, Puja J. Umaretiya, Erika Hanson, Kira Bona

Blood (2024) 144 (Supplement 1): 402.

https://doi.org/10.1182/blood-2024-210754

Published: 2024

Journal Articles

Food Insecurity and Cardiovascular Risk Among Survivors of Pediatric Hematologic Malignancies

Rahela Aziz-Bose, Lucille Lokko, Morgan A. Paul, Colleen A. Kelly, Leanne Duhaney, Puja J. Umaretiya, Fang Fang Zhang, Lisa B. Kenney, Kira Bona

Blood (2024) 144 (Supplement 1): 5130.

https://doi.org/10.1182/blood-2024-199220

Published: 2024

Journal Articles

Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies

Rahela Aziz-Bose, Morgan A. Paul, Yael Flamand, Colleen A. Kelly, Leanne Duhaney, Puja J. Umaretiya, Lucille Lokko, McKenzie Griffin, Alexandria Hawkins, Peter D. Cole, Lisa M. Gennarini, Justine M. Kahn, Kara M. Kelly, Victoria B. Koch, Bruno Michon, Thai Hoa Tran, Jennifer J.G. Welch, Lewis B. Silverman, Kira Bona

Blood (2024) 144 (Supplement 1): 3750.

https://doi.org/10.1182/blood-2024-205672

Published: 2024

Journal Articles

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Blood (2016) 128 (22): 177.

https://doi.org/10.1182/blood.V128.22.177.177

Published: 2016

Journal Articles

Results Of The DFCI ALL Consortium Protocol 05-001 For Children and Adolescents With Newly Diagnosed ALL

Lewis B. Silverman, MD, Kristen E. Stevenson, MS, Uma H. Athale, M.D., M.Sc., Luis A. Clavell, MD, Peter Cole, MD, Kara A. Kelly, MD, Jean-Marie Leclerc, MD, Bruno Michon, MD, FRCPC, Marshall A. Schorin, MD, Cindy L Schwartz, MD, MPH, Barbara Asselin, MD, Jeffrey G Supko, PhD, Sarah Hunt, MPH, Place Andrew, MD, PhD, Lynda M. Vrooman, MD, Donna S. Neuberg, ScD, Stephen E. Sallan, MD

Blood (2013) 122 (21): 838.

https://doi.org/10.1182/blood.V122.21.838.838

Published: 2013

Journal Articles

Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients

Michael Andreeff, MD, PhD, Zhihong Zeng, PhD, Mary A Kelly, RN, Rui-yu Wang, MD, PhD, Teresa McQueen, BS, Seshagiri Duvvuri, Gul Nowshad, Gautam Borthakur, MD, Jan A. Burger, MD, PhD, Tapan M. Kadia, M.D., Elias Jabbour, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD, PhD

Blood (2012) 120 (21): 142.

https://doi.org/10.1182/blood.V120.21.142.142

Published: 2012

Journal Articles

Familial and Acquired SH2B3 mutations in ALL

Arianne Perez-Garcia, PhD, Charles A. LeDuc, PhD, Kara A. Kelly, MD, Chaim Jalas, Wendy K Chung, MD, PhD, Adolfo A. Ferrando, MD, PhD

Blood (2012) 120 (21): 1326.

https://doi.org/10.1182/blood.V120.21.1326.1326

Published: 2012

Journal Articles

Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL)

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Tapan M. Kadia, M.D., Jan A. Burger, MD, PhD, Gautam Borthakur, M.D., Jorge E. Cortes, MD, Naval Daver, MD, Elias J. Jabbour, MD, Charles Asa Koller, Marina Konopleva, MD, PhD, Naveen Pemmaraju, M.D., Marry A Kelly, Rebecca Garris, BSc, Susan O'Brien, Stefan Faderl, MD

Blood (2012) 120 (21): 1501.

https://doi.org/10.1182/blood.V120.21.1501.1501

Published: 2012

Journal Articles

Phase II Study of the Histone Deacetylase Inhibitor Panabinostat (LBH589) in Patients with Low or Intermediate-1 Risk Myelodysplastic syndrome

Sophie Dimicoli, MD, PhD, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Zeev Estrov, Hui Yang, MD, PhD, Mary A Kelly, RN, Sherry Pierce, RN, BS, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2011) 118 (21): 1731.

https://doi.org/10.1182/blood.V118.21.1731.1731

Published: 2011

Journal Articles

A Stat5b transgene is capable of inducing CD8 + lymphoblastic lymphoma in the absence of normal TCR/MHC signaling

Katherine Bessette, Mark L. Lang, Roy A. Fava, Martin Grundy, Jennifer Heinen, Laurie Horne, Rosanne Spolski, Amin Al-Shami, Herbert C. Morse, III, Warren J. Leonard, John A. Kelly

Blood (2008) 111 (1): 344–350.

https://doi.org/10.1182/blood-2007-04-084707

Published: 2008

Includes: Supplemental data

Journal Articles

A Dose Escalation Study of the Pharmacokinetics, Safety & Efficacy of Deferitrin, an Oral Iron Chelator in Beta Thalassaemia Patients.

R. Galanello, G. Forni, A. Jones, A. Kelly, A. Willemsen, X. He, A. Johnston, D. Fuller, J. Donovan, Antonio Piga

Blood (2007) 110 (11): 2669.

https://doi.org/10.1182/blood.V110.11.2669.2669

Published: 2007

Journal Articles

Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor.

Jorge Cortes, James M. Foran, Marcel P. Devetten, Francis J. Giles, Joyce James, Patrick P. Zarrinkar, Michael H. Silverman, Kerry A. Kelly, Norman M. Padre, Shripad Bhagwat, Wendell Wierenga

Blood (2007) 110 (11): 1597.

https://doi.org/10.1182/blood.V110.11.1597.1597

Published: 2007

Journal Articles

GRN163L, a Potent and Specific Inhibitor of Telomerase: Integrated Pharmacokinetic, Pharmacodynamic, and Safety Data Guides Design of Practical Treatment Regimens for Targeting Inhibitory Levels in Patients.

Robert J. Tressler, PhD, Allison C. Chin, Ph.D., Eric J. Feldman, M.D., Kanti R. Rai, M.D., Doug Kornbrust, Ph.D., Calvin B. Harley, Ph.D., Melissa A. Kelly Behrs, Laurence Elias, MD

Blood (2006) 108 (11): 2595.

https://doi.org/10.1182/blood.V108.11.2595.2595

Published: 2006

Journal Articles

Thrombocytopenia identifies a severe familial phenotype of systemic lupus erythematosus and reveals genetic linkages at 1q22 and 11p13

R. Hal Scofield, Gail R. Bruner, Jennifer A. Kelly, Jeff Kilpatrick, Debra Bacino, Swapan K. Nath, John B. Harley

Blood (2003) 101 (3): 992–997.

https://doi.org/10.1182/blood-2002-04-1003

Published: 2003

Journal Articles

Human Follicular Dendritic Cells Inhibit Superantigen-Induced T-Cell Proliferation by Distinct Mechanisms

Anthony W. Butch, Kathleen A. Kelly, Michael S. Willbanks, Xinwen Yu

Blood (1999) 94 (1): 216–224.

https://doi.org/10.1182/blood.V94.1.216.413k34_216_224

Published: 1999

NARROW

Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001

Pediatric RISE: Development of a Poverty-Targeted Cash Support Intervention for Pediatric Cancer

Food Insecurity and Cardiovascular Risk Among Survivors of Pediatric Hematologic Malignancies

Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Results Of The DFCI ALL Consortium Protocol 05-001 For Children and Adolescents With Newly Diagnosed ALL

Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib: Results From a Phase I Trial in Relapsed/Refractory AML Patients

Familial and Acquired SH2B3 mutations in ALL

Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL)

Phase II Study of the Histone Deacetylase Inhibitor Panabinostat (LBH589) in Patients with Low or Intermediate-1 Risk Myelodysplastic syndrome

A Stat5b transgene is capable of inducing CD8 + lymphoblastic lymphoma in the absence of normal TCR/MHC signaling

A Dose Escalation Study of the Pharmacokinetics, Safety & Efficacy of Deferitrin, an Oral Iron Chelator in Beta Thalassaemia Patients.

Human Pharmacokinetics of AC220, a Potent and Selective Class III Receptor Tyrosine Kinase Inhibitor.

GRN163L, a Potent and Specific Inhibitor of Telomerase: Integrated Pharmacokinetic, Pharmacodynamic, and Safety Data Guides Design of Practical Treatment Regimens for Targeting Inhibitory Levels in Patients.

Thrombocytopenia identifies a severe familial phenotype of systemic lupus erythematosus and reveals genetic linkages at 1q22 and 11p13

Human Follicular Dendritic Cells Inhibit Superantigen-Induced T-Cell Proliferation by Distinct Mechanisms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only